Drug Profile

Manganese chloride tetrahydrate - Ascelia Pharma

Alternative Names: CMC-001; Mangoral^®; Orviglance

Latest Information Update: 11 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CMC Contrast
Developer Ascelia Pharma
Class Contrast media; Heavy metals
Mechanism of Action Magnetic resonance imaging enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Liver disorders
New Molecular Entity No

Highest Development Phases

Preregistration Liver disorders

Most Recent Events

09 Feb 2026 The US FDA accepts Orviglance® NDA for review for Liver disorder
09 Feb 2026 Efficacy data from a phase III trial in Liver disorder released by Ascelia Pharma
05 Feb 2026 FDA assigns PDUFA action date of (03/07/2026) for Orviglance® for Liver disorders

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com